Loading
Life sciences · Journal article
Biomacromolecules · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Breast cancer is a highly prevalent malignancy, but the conventional single chemotherapy suffers from insufficient therapeutic outcomes. To overcome this challenge, this study developed a dextran-based prodrug nanogel (DDIR) with dual pH/GSH responsiveness to the tumor microenvironment, enabling near-infrared (NIR) fluorescence−photothermal dual-modal imaging-guided chemo-photothermal synergistic therapy. Specifically, DDIR was prepared by conjugating doxorubicin to aldehyde-functionalized dextran via acid-sensitive Schiff-base linkages, crosslinking with a disulfide-containing linker, and encapsulating the NIR-II photothermal agent IR-1061 through hydrophobic interactions. In the acidic tumor microenvironment with elevated glutathione (GSH) levels, DDIR release drugs of DOX and IR-1061, and efficiently suppresses tumor proliferation, and ablates tumor lesions in tumor-bearing mice. This study provides a novel theranostic platform for the synergistic treatment of breast cancer and holds a promising potential for clinical translation.